Purpose: To determine the incidence and management of clinically significant bleeding after percutaneous radiofrequency ablation (pRFA) of hepatic tumors and to evaluate the need for angiographic intervention (AI) in patients with active contrast extravasation (CE) on immediate post-ablation imaging. Materials: In this IRB approved, HIPAA compliant study, CT and clinical data were retrospectively reviewed of consecutive patients (3/2006-9/2014) who underwent pRFA of hepatic tumors. Patients were evaluated for the need of care escalation and AI for ablation-related bleeding. Results: 339 patients (422 tumors) treated with pRFA were included. 119 (35.1%) patients required hospitalization following ablation. 74/119 (62.1%) had a peri-hepatic hematoma (PH), and 10/119 (8.4%) had CE on immediate post RFA imaging. 9/119 (7.6%) requiring escalation of care to an ICU based on imaging findings did not have subsequent clinical evidence of bleeding. 6/339 (1.7%) patients required AI due to clinically significant bleeding with 1/339 (0.3%) death despite angiographic and surgical interventions. The average hospital stay of patients with PH, CE, or lack of thereof was 2.5, 1.6 and 2 days respectively (p¼0.47 and 0.28). Patients with PH or CE were not more likely to undergo AI compared to patients without PH or CE (p¼0.14 and 0.13). Conclusions: Peri-hepatic hematoma or active contrast extravasation seen on immediate contrast-enhanced CT after hepatic tumor ablation does not necessitate escalation of care or prolonged hospital stay and can be managed conservatively in most patients. Specifically, post-ablation contrast extravasation does not equate to unstable bleeding and need for immediate angiography.

